Dvora Shmulewitz1,2, Jacquelyn L Meyers3, Melanie M Wall1,2,4, Efrat Aharonovich1,2, Amos Frisch5,6, Baruch Spivak5, Abraham Weizman5,6,7, Howard J Edenberg8, Joel Gelernter9, Deborah S Hasin1,2,3. 1. Department of Psychiatry, Columbia University, NewYork, NewYork. 2. NewYork State Psychiatric Institute, NewYork, NewYork. 3. Department of Epidemiology, Mailman School of Public Health, Columbia University, NewYork, NewYork. 4. Department of Biostatistics, Mailman School of Public Health, Columbia University, NewYork, NewYork. 5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Felsenstein Medical Research Center, Petach Tikva, Israel. 7. Research Unit, Geha Mental Health Center, Petach Tikva, Israel. 8. Departments of Biochemistry and Molecular Biology and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana. 9. Departments of Psychiatry and Genetics and Neurobiology, Yale University School of Medicine, New Haven, Connecticut.
Abstract
OBJECTIVE: Nicotine craving is considered an important element in the persistence of cigarette smoking, but little is known about the role of craving in the widely recognized association between variants mapped to the neuronal nicotinic acetylcholine receptor (CHRN) genes on chromosome 15 and nicotine phenotypes. METHOD: The associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerström Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample. Indirect effects of genotype on nicotine phenotypes through craving were formally tested using regression and bootstrapping procedures. RESULTS: At CHRNA3, allele G of rs3743078 was associated with increased craving, CPD, and FTND scores: Participants with one or two copies of the G allele had, on average, higher scores on the craving scale (p = .0025), more cigarettes smoked (p = .0057), and higher scores on the FTND (p =.0024). With craving in the model, variant rs3743078 showed a significant indirect effect through craving on CPD (p = .0026) and on FTND score (p = .0024). A sizeable proportion of the total rs3743078 effect on CPD (56.4%) and FTND (65.2%) was indirect through craving. CONCLUSIONS: These results suggest that nicotine craving may play a central role in nicotine use disorders and may have utility as a therapeutic target.
OBJECTIVE:Nicotine craving is considered an important element in the persistence of cigarette smoking, but little is known about the role of craving in the widely recognized association between variants mapped to the neuronal nicotinic acetylcholine receptor (CHRN) genes on chromosome 15 and nicotine phenotypes. METHOD: The associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerström Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample. Indirect effects of genotype on nicotine phenotypes through craving were formally tested using regression and bootstrapping procedures. RESULTS: At CHRNA3, allele G of rs3743078 was associated with increased craving, CPD, and FTND scores: Participants with one or two copies of the G allele had, on average, higher scores on the craving scale (p = .0025), more cigarettes smoked (p = .0057), and higher scores on the FTND (p =.0024). With craving in the model, variant rs3743078 showed a significant indirect effect through craving on CPD (p = .0026) and on FTND score (p = .0024). A sizeable proportion of the total rs3743078 effect on CPD (56.4%) and FTND (65.2%) was indirect through craving. CONCLUSIONS: These results suggest that nicotine craving may play a central role in nicotine use disorders and may have utility as a therapeutic target.
Authors: Megan E Piper; Thomas M Piasecki; E Belle Federman; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2004-04
Authors: Richard Sherva; Henry R Kranzler; Yi Yu; Mark W Logue; James Poling; Albert J Arias; Raymond F Anton; David Oslin; Lindsay A Farrer; Joel Gelernter Journal: Neuropsychopharmacology Date: 2010-05-19 Impact factor: 7.853
Authors: Jennifer B Listman; Deborah Hasin; Henry R Kranzler; Robert T Malison; Apiwat Mutirangura; Atapol Sughondhabirom; Efrat Aharonovich; Baruch Spivak; Joel Gelernter Journal: BMC Genet Date: 2010-06-14 Impact factor: 2.797
Authors: Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Gerald A Deehan; Sheketha R Hauser; Bruk Getachew; R Aaron Waeiss; Eric A Engleman; Christopher P Knight; William J McBride; William A Truitt; Richard L Bell; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2018-07-24 Impact factor: 4.530